

Inflammatory biomarkers and perinatal depression: a systematic review

¹Anabela Silva-Fernandes*

²Ana Conde*

³Margarida Marques

^{4,5}Rafael A. Caparros-Gonzalez

⁶Emma Fransson

¹Ana Raquel Mesquita

¹Bárbara Figueiredo

⁶Alkistis Skalkidou

*Both authors contributed equally to this work

Affiliations:

¹Center for Research in Psychology (CIPsi), School of Psychology, University of Minho, Portugal

²Portucalense Institute for Human Development. Portucalense University, Portugal

³Faculdade de Psicologia, Universidade de Lisboa, Lisbon, Portugal

⁴Faculty of Health Sciences, Department of Nursing, University of Granada, Spain

⁵Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain

⁶Department of Women's and Children's Health, Uppsala University, Sweden

Corresponding author:

Alkistis Skalkidou, MD, PhD

Department of Women's and Children's Health,

Uppsala University

Kvinnokliniken, Akademiska sjukhuset

Uppsala, 75185 SWEDEN

alkistis.skalkidou@kbh.uu.se

Abstract

Background: Approximately 10 to 20% of pregnant women worldwide experience perinatal depression (PND), a depressive episode with onset during pregnancy or after childbirth. We performed a systematic review to identify, summarize and discuss studies on inflammatory biomarkers described in relation to PND.

Methods: Inclusion criteria defined the selection of observational studies written in English, French, Spanish or Portuguese, that evaluate analytical levels of inflammatory molecules (protein levels) in biological fluids in women, with a diagnosis of depression using ICD/DSM diagnostic criteria or depressive symptoms assessed by standardized psychometric instruments, during pregnancy and/or postpartum. Case reports, experimental studies, reviews, qualitative analysis, meta-analysis, gray literature or replicated data were excluded. Three electronic databases were used for search (Pubmed, Web of Science and PsychInfo) and quality assessment of selected studies were performed using the Newcastle-Ottawa Scale. Data extraction included study design; number of subjects; obstetric information; tools and timepoints of depression and inflammatory markers assessment.

Results: 56 studies where the major aim was to analyze the association between depression and inflammatory biomarkers during pregnancy and postpartum period were included in this systematic review. Overall, the findings of our systematic review lend support to the hypothesis that several inflammatory markers may be associated with peripartum depressive symptoms. The associations were somewhat different looking at pregnancy compared to the delivery time-point and postpartum, and mainly referred to increased levels of IL-6, IL-8, CRP and TNF- α among depressed.

Discussion: Our results revealed high heterogeneity in relation to the timing of biological sampling for markers, as well as timing and instruments used for depression assessment within the perinatal period for the different studies. Studies differed also in

relation to use of biomarkers or depression as exposure and outcome respectively, and whether these were addressed at the same timepoint or separate ones.

Given the high burden of PND on women, children and families, it is crucial to try to harmonize methods used in related studies, in order to be able to pool results that could give us insights into the pathophysiological mechanisms behind how the immune system and PND are connected; this could have great impact on early detection, prevention and even treatment of PND.

Keywords

depression, pregnancy, postpartum, perinatal, immune system, biomarkers, cytokines, inflammation

1. Introduction

Pregnancy and postpartum are critical periods for the mental health of the mother, her baby and the whole family. During the past decades, knowledge regarding the psychobiological pathways impacting on mental health has expanded substantially, including studies in the perinatal setting. While epidemiological literature still dominates the perinatal mental health field, increasing evidence supports the link between psychosocial and biological pathways, and more studies focus on the role of the immune system in the development of perinatal depression (PND), both with antenatal (AND) and postpartum onset (PPD) (e.g., (1-4)).

The immune system is a complex network that aims to protect the host from invading microorganisms and induce wound healing when needed. During an immune response, such as the system's reaction to an infection, human behavior is affected, leading often to increased inactivity, increased sleepiness, decreased appetite, and social withdrawal, behaviors that also resemble those characteristic of clinical depression (5, 6). These so-called sickness behaviors can also be induced by cytokines or experimental exposure to endotoxins (7, 8).

The interplay between the immune functioning and depression has been explored over the last decades and a bidirectional loop has been described. While inflammation seems to play a key role in depression's pathogenesis, at least for a subset of depressed individuals, it was also been shown that depression, adversity and stress have also been associated to exaggerated or prolonged inflammatory responses (for a review see (9)). Thus, studying the pathways involved in this interplay could allow to identify inflammatory biomarkers with the potential to predict depression, but also possible targets for prevention and/or treatment.

As many bodily systems, the immune system undergoes large changes to adapt to the pregnancy and postpartum period. An inflammatory response is necessary to promote implantation (10, 11), while during pregnancy, the maternal immune system is challenged by the semi-allogeneic fetus and needs to adapt, mainly by a shift towards immune tolerance, characterized i.e. by an increase in regulatory T-cells (Tregs) as well as macrophages type 2 (M2) (12, 13).

The dramatic shift in the characteristics of the immune response during pregnancy and postpartum seem to impact on maternal pregnancy mood and in some way differently across time (14). The increase in Treg occurring in mid-pregnancy coincide with the pregnancy period when most women report increased wellbeing, and Treg activity has been associated with resilience to stress in animal studies (15). Furthermore, women with chronic autoimmune conditions, such as multiple sclerosis (MS) and rheumatoid arthritis (RA) often experience remission of the conditions during this pregnancy period (16). In the third trimester, pro-inflammatory activity rise and the delivery itself could be characterized as a largely pro-inflammatory event, including the remodeling of the cervical tissue as well as uterine contractions (17, 18). This intensification of pro-inflammatory activity in late pregnancy co-occurs with an increase in depressive symptoms during this period, compared to lower levels in the second trimester (19).

After childbirth, maternal body needs to reduce the pro-inflammatory activity, and a decrease of many inflammatory markers has been reported from the third trimester to the postpartum (20, 21). For many women, this period is characterized by additional bodily changes associated with wound healing and breast-feeding onset that could also impact on immune actions. Furthermore, sleep disturbances that are common perinatally, are also known to induce a pro-inflammatory state (22) affecting depression

risk. The early postpartum period has been characterized by a drop in Treg cells, and immune response characteristic of T helper 1 (Th1) or Macrophages type 1 has been described (23). While MS and RA often improves during pregnancy, these conditions worsen again postpartum (16). These changes in the immune system seems also to be associated to an increased risk of depression during the postpartum period (e.g., (1, 24, 25)).

A previous systematic review on postpartum depression included 25 articles (26). Their most robust finding was that levels of CRP in late pregnancy could predict postpartum depression. However, many new studies on this topic have been published and techniques for biomarker analyses have developed further and more focus has been given to depression with antenatal onset. A recent meta-analysis of inflammatory markers for major depression in general and specifically perinatally, showed robust results of increase of several pro-inflammatory markers in depressed individuals (27). Some studies of specific inflammatory biomarkers in the perinatal setting show conflicting results. A more recent review of literature has precisely reflected on the distinct and changing inflammatory profiles throughout pregnancy and postpartum which makes the study of depression-related alterations in these periods highly complex (14). Contributing to this complexity is the fact that many studies in the field utilize diverse methodologies that make difficult to compare findings in order to understand the interplay between the biological processes involving the adjustments of the immune system during pregnancy and postpartum and the trajectories of change of mental health during this period. Despite the growing evidence in the field of immune related biomarkers in PND and PPD, clinical applications for biomarkers for depression prediction or treatment during these periods are lacking in clinical practice.

In order to address this shortcoming of earlier studies and achieve a better categorization of the scientific output exploring the associations between the functioning of the maternal immune system and PND, we performed a systematic review involving all the original empirical quantitative studies conducted during the perinatal period, which assessed both levels of women's inflammatory molecules as well as depression (diagnosis of depression or depressive symptoms or depressive symptomatology), while (1) taking into account whether the assessments of the two variables were performed cross-sectionally at one time-point or longitudinally and even (2) if one of the variables could be used as a predictor for the other.

2. Methods

This study followed the recommendations outlined in the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines (28, 29) and has been registered on PROSPERO (Registration ID: CRD42020210080). Protocol details are available at

https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=210080.

2.1. Search strategy

An initial article search was conducted at July 3rd, 2020, through three electronic databases (Pubmed, Web of Science and PsychInfo) to identify English, Portuguese, French and Spanish-language human studies unrestricted by year of publication (for search terms see S1 Table). In February 23rd, 2022, a new search was conducted using the same search formula and filters (with the exception of the Filter "Journal Article" in Pubmed that is no longer available) to determine new entries. After duplicates removal, the unique entries from this new search were identified by table comparison.

Duplicates detection was performed by two independent reviewers (ASF and MM) on two different platforms (Endnote and Rayyan) using manual review by ordering articles by title, authors, pages, journal. Finally, the authors met to reach accordance on the final number of duplicates.

2.2. Studies selection

Original quantitative studies that evaluate the levels of inflammatory molecules in women with a diagnosis of depression or depressive symptomatology conducted in women during pregnancy and/or at the postpartum period were eligible for this systematic review. Two authors (ASF and MM) screened the titles and abstracts of articles from the primary search independently against inclusion and exclusion criteria:

Inclusion criteria:

- Written in English or French or Spanish or Portuguese
- Observational studies
- Depression assessed using ICD/DSM diagnostic criteria either through diagnostic interview or expert opinion. Alternatively, depressive symptomatology assessed using standardized psychometric instruments
- Inflammatory molecules measurement (protein levels) in biologic fluids using analytical techniques

Exclusion criteria:

- Case reports or experimental studies or reviews or qualitative analysis or meta-analysis or gray literature
- Replicated data

The full text of qualifying articles was then assessed against the same standard by different pairs of authors (ASF&MS; AC&ARM; BF&RCG; AS&MM). Any

discrepancies were resolved first through discussion amongst the pair, and if a consensus could still not be reached, by conferring with other group members.

2.3 Data extraction

The following data was extracted from each selected study: country of origin; study design; number of subjects; socio-economic status/ethnicity; obstetric information, namely delivery mode; assessment of depression: instrument(s) and timepoint(s) and inflammatory protein markers: biological fluid/hour of collection, timepoint(s), dosage assessment technique, inflammatory markers and results.

2.4 Quality assessment

Following PRISMA guidelines, the quality assessment of selected studies (RCG&MM) and the data extraction were conducted independently by two authors. At the end, the complete data extraction table was revised to uniformization. Different version of the Newcastle-Ottawa Scale (NOS) were used to assess the methodological quality of selected studies (30-32). All the inter-rater agreements between authors were verified prior to resolving disagreements.

3. Results

A total of 3527 relevant references were initially identified in an electronic search of three databases: Pubmed, Web of Science and PsychInfo. All 806 duplicated references were removed, and 2721 articles remained. The titles and abstracts of the identified references were screened, and 2594 non-relevant references were excluded. The full text of the 127 remaining studies was then screened, and 44 studies met one or more

exclusion criteria. At the final stage, 83 studies were included in the review. A flow diagram of the search selection for the included studies is presented in Fig. 1.

Fig 1. The PRISMA flow diagram.

From the 83 studies included in the qualitative analysis 27 were studies in which the association between depression and inflammatory markers wasn't the principal aim but since this derived data was available, we performed data extraction from these studies and presented them in the S2 Table.

For the accomplishment of the aims of this systematic review we have focused the 56 studies where the major aim was to analyze the association between depression and inflammatory biomarkers during pregnancy and the postpartum period. Considering the study design used, 8 studies (3 of which with prospective analysis) used a case-control design, 20 studies a cross-sectional, and 27 a cohort analysis design. Thirty one studies involved repeated assessment time points and longitudinal analyses both during pregnancy (4 studies) and from pregnancy to postpartum (27 studies).

The studies included originate from different countries and research settings, while the involved participants present with markedly different sociodemographic and clinical features (e.g., with and without psychosocial risks). Further, depression was assessed with different methods, from self-reported questionnaires for assessing depressive symptoms, depressive mood, depressive symptomatology or clinical interviews for diagnosing depressive disorders. Lastly, inflammation-related molecules were assessed with very different techniques.

Due to this diversity, results are presented in two steps. Firstly, cross-sectional, and case-control studies on inflammatory biomarkers and depression are presented accordingly to the period involved (pregnancy or postpartum) (for details see Table 1). Secondly, longitudinal studies are presented, with a note on whether a study included predictive analyses (for details see Table 2).

Quality assessment

Two researchers analyzed 56 articles for quality assessment. The inter-rater reliability between authors was analyzed calculating the agreement percentage (84%) and Cohen's kappa ($K=0.777$), significance p -value $< .001$.

Associations between inflammatory biomarkers and depression during pregnancy and during the postpartum period

Antenatal depression

Fourteen studies (4 case-control and 10 cross-sectional) exclusively assessed the association between depression and inflammatory biomarkers during pregnancy. Most of these studies were implemented during the 2nd and 3rd trimesters and used self-reported questionnaires to measure depressive symptoms / symptomatology (both using continuous scores and cut-off points) or depressive mood (33). Additional studies also included diagnosis of depression to define the depressed group (34-40).

Most of the studies found an association between several inflammatory biomarkers and depression status. In general, higher levels of mostly pro-inflammatory markers (namely, CRP, IFN- γ /IL-4 ratio, IL-1 β , IL-1R, IL-5, IL-6, IL-8, IL-9, IL-12, IL-13, IL-23, IL-33 and TNF- α) were associated to higher depressive symptomatology

or observed in depressed groups. For example, groups with higher depression symptoms demonstrated significantly higher circulating CRP levels (41) in comparison with those with lower depression symptom scores. Increased levels of CRP were also observed in a group with depression and trauma, in comparison to healthy pregnant volunteers (39). Additionally, a positive correlation between CES-D scores and IL-1 β (42) was found, as well as higher IL-1 β in the CSF showing a significant association with increases odds of PND (37). Among other markers investigated, positive correlations were also found between IFN- γ /IL-4 ratio, IL-5, IL-9, IL-12 and IL-13 and EPDS scores (43). IL-1RA levels were significantly higher in women with high scores for depressive symptoms (CES-D>20) in comparison with women having scores less than 20 (44). Higher cerebrospinal fluid IL-1b, IL-23 and IL-33 concentrations at pre-cesarean time were significantly associated with increased odds of perinatal depression (37). Higher levels of TNF- α in depressed pregnant women were found when compared to controls in three studies (35, 38, 41). Nevertheless, these findings were not similar across all studies. Six studies had no significant results in (33, 34, 36, 40, 45, 46) (Table 1); one of them showing marginal p-values for higher CES-D scores as a predictor for higher levels of IL-6 and TNF- α (45).

In contrast with most of the studies in which a concrete small number of inflammatory proteins levels were determined, one study performed an immunoassay of a panel of 92 inflammatory proteins. Lower levels of 23 mostly anti-inflammatory proteins were found in women with antenatal depression (top three: TRAIL, CSF-1, CX3CL1) and women on SSRI treatment (top three: CSF-1, CEGF-A, IL-15RA) in comparison with controls (36) (Table 1).

In respect to markers representing the tryptophan kynurenine pathway, e.g. tryptophan (TRP) and/or kynurenine (KYN) and/or the ratio KYN/TRP were assessed

in ten studies: two during pregnancy (41, 46); seven involving both pregnancy and postpartum (3, 4, 47-51); and one at postpartum (52). Findings point out some mixed results, considering the assessment time point considered and the statistical associations studied. In general, higher Kyn and Kyn/Trp ration was found in depressed group compared to controls, both during pregnancy (3, 47) and at postpartum (48). However, these results are not consistent, with no significant associations being found between KYN and KYN/TRP and depressive symptoms (51) or even describing the association in the opposite direction (4). Concerning TRP, findings showed no associations between TRP levels and prenatal depression (4, 51).

Among other markers investigated, most indicated a pro-inflammatory immune response in association with depressive symptoms, across the perinatal period; increase of LPS (53) and neopterin levels were found (54) whereas no differences were found for ERVWE1 levels (Human Endogenous Retrovirus WEnvC7-1 Envelope Protein) between women affected by PND and healthy controls (40).

Postpartum depression

The methodological diversity of the eleven studies assessing the association between inflammatory biomarkers and depression during postpartum is even larger than in the studies implemented during pregnancy. The time frame varied between one week and 12 months postpartum, but most studies were conducted between 4-12 weeks postpartum. Depressive symptoms or symptomatology was analyzed in four studies (#2, #48, #57, #83), depressive mood in three studies (#23, #45, #63), and diagnosis of depression in five studies. A diversity of inflammatory biomarkers assessed was also found, namely IFN- γ , IL-1 α , IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL12, IL-13, IL-17, IL-18, TGF- β 2, TNF- α and other inflammation-related molecules.

Most of the studies found an association between inflammation and depression postpartum, except two studies (55, 56). Increased levels of IL-6 were associated with higher depressive symptomatology in two different studies (52, 57) (assessed with EPDS, SCID-5 and CES-D). Both (52, 57) were cross-sectional studies with the time point of assessment around 8 weeks postpartum. IL-8 levels were also in five studies and found to be positively associated with depression symptoms in 4 different studies all with a cross-sectional design (52, 57-59). The study of Fransson, E and colleagues (59), interestingly assessed how depression during late pregnancy affects inflammation around childbirth; this association was only in the group of women with premature delivery (representing 42 % of the total sample); the other 3 studies included later periods of assessment.

TNF-alpha, measured in four studies, was also shown to be significantly and positively associated with depression in one study (57), negatively associated with depressive symptoms when CpG-induced TNF-alpha was measured (60) and with no significant associations observed in the other two studies (52, 58). Specifically in the study from Christian et al. (57) the association between TNF-alpha and depressive mood (CES-D) was only found in a sample of African American women assessed between the 7 and 10 postpartum weeks.

Increased levels of other immunological mediators have also shown to be associated with depressive symptomatology, namely IL-2 (58), TGF-beta2 (61) and IgG (62). On the other hand, negative associations were described in 3 studies. Two found serum INF-gamma levels to be negatively associated with depressive symptomatology between the 4-6 weeks postpartum (63, 64). Also in a cross-sectional study, but congregating data from women participating at 12, 24 and 36 months postpartum, Gruenberg and collaborators have shown decreased induced-levels INF-gamma and

other several cytokines, such as IL-8, TNF-alpha, IL-4, IL-5, IL-10 and IL-13, assessed from peripheral blood mononuclear cells associated with EPDS scores above 12 (60). Decreased levels of IL-2 have also been reported to be associated with increased risk for depressive symptomatology (52).

A lower ratio of KYN and of KYN/TRP ratio is observed during the postpartum period to that during pregnancy (47) and an increase in the K/T quotient over the postpartum period (48) was found in depressed group compared to controls. KYN levels and KYN/TRP ratio were found to be related with EPDS scores during postnatal period (47), and KYN/TRP ratio with the changes in EPDS from pregnancy to 12 months postpartum (4). Lastly, one study reported lower CC16 (considered anti-inflammatory) in women with postpartum depression (65).

Longitudinal studies, some including predictive approaches

Of the 31 longitudinal studies investigating the association between inflammatory biomarkers and depression over time, 4 were focused on the pregnancy period, five on the postpartum period and 22 across both pregnancy and postpartum. Various biomarkers were used for the investigations of association with depressive symptoms measured longitudinally (namely, 3HK and 3HAA, AA, CC16, CRP, GM-CSF, IFN- γ , IL-1 β , IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-6R, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, KA, KYN, leptin, LIF-R, LPS, MCP/CCL2, MCP-1, MIP-1 α , MIP-1 β , sgp130, TNF- α and TRP), although the most common findings regarded CRP, IL-6, TNF-alpha, KYN and TRP.

This study also demonstrated that IL-6 and TNF -alpha levels at birth were predictors of symptomatology at 1 and 6 weeks postpartum. This result was also corroborated by study (66), which also found IL-6 levels at delivery (within 48h) as an

independent predictor of depressive symptoms assessed 6 months postpartum. Increased levels of other immunological mediators have shown to be associated with depressive symptomatology, namely CXCL1, FGF-23, HGF, IL-18, TRANCE (67), IL-1beta (68) and CRP (66).

Among the studies focusing C-reactive protein (CRP), three showed higher CRP levels in association to prepartum depression and lower CRP levels in postpartum depression in the same two studies (50, 51) (sample overlap) and (69). The reports for TNF- α showed significant results in 4 studies. Although three of them showed lower TNF- α in PPD group (70) or in association with lower EPDS scores (24, 71), another study displays a higher TNF- α at 8-12 gestational weeks in depressed subjects vs. a healthy group, even when BMI, age and race were controlled for (53). Decreased levels of inflammatory markers were found in a depressive symptoms group vs. controls after adjusting for multiple testing, where women with PPD presented higher plasma levels for five inflammatory markers: CXCL1, FGF-23, HGF, IL-18 and TRANCE (25). The opposite was nevertheless true for the panel of 23 molecules considered in a study (72), where higher levels of inflammatory biomarkers were found in depressed group vs. controls; here, a different slope of change for cytokines (IL-6, CCL3, IL-15, G-CSF) was reported between depressed and non-depressed women. In turn, considering the 17 molecules assessed in the study (73) only MIP-1 β showed a positive correlation with depressive symptoms.

Of the 22 longitudinal studies across pregnancy and the postpartum period, eight examined the potential predictive role of either inflammatory markers in the later depressive symptoms, or of depressive symptoms in predicting later inflammation profiles. One study showed higher depressive symptoms as a predictor for higher levels of IL-6 at midgestational period, as well as a significant association between increase in

depressive symptoms from early to mid-gestation and IL-6 levels (74). In the same study, higher depressive symptoms at early or midgestational predict higher levels of CRP levels at midgestational period (74). Further, another study showed that lower IL-6 levels in the 3rd trimester predicted higher EPDS scores postpartum (1). In another study, family history of depression, third semester cortisol AUC, and third semester IL8/IL10 predicted symptoms of PPD (68). Moreover, increased IL-6 levels were found in depressed groups vs. controls at 24-28 gestational weeks (53), both before and after delivery (75). Additionally, higher IL-6 levels were associated with higher prenatal (3, 4) and postnatal EPDS scores (4), as well as with changes in EPDS across pregnancy (3, 4, 76). Lower prenatal Kyn levels were associated with greater depressive symptoms in late pregnancy, with prenatal Trp levels and Kyn/Trp ration moderating the association between IL-6 levels both antenatally and postpartum (4). One study found that cytokines and tryptophan metabolites predicted depression during pregnancy and that IL-1 β and IL-6 levels were associated with severity of depression symptoms during pregnancy and postpartum (3). Centering in the longitudinal studies implemented during the postpartum period, the study conducted by Boufidou (2) showed that the TNF-alpha levels assessed in the CSF during labor significantly predicted increased depression symptoms at either 1st and 6th weeks postpartum, while serum CSF was only associated with the symptomatology at the 1st week postpartum.

4. Discussion

The present systematic review explored the association between a variety of inflammatory markers and depression, in different time points from pregnancy to postpartum period. Despite the large volume of available evidence stemming from 83 studies, a combined quantitative synthesis of all eligible studies was not feasible owing

to the large variability in inflammatory markers assessed, the different study designs (cross-sectional, case-control and longitudinal studies), the different windows of exposure or outcome assessment, and the methods used for assessment for both depression and inflammatory markers.

Most studies assessed cross-sectional associations, while some few tried to assess the predictive potential of inflammatory markers for depression at later time-points, or of depressive symptoms to predict later inflammatory states. Overall, the findings of our systematic review lend support to the hypothesis that several inflammatory markers may be associated with peripartum depressive symptoms. The associations were somewhat different looking at pregnancy compared to the delivery time-point and postpartum, and mainly referred to increased levels of IL-6, IL-8, CRP and TNF- α among depressed. Evidence on the association of other inflammatory markers and PPD remains more inconclusive and replication studies are needed.

Inflammatory markers are a very broad family of heterogenous components, which have long been reported to play a significant role in the pathogenic pathways of several neurological and psychiatric diseases (77, 78). In addition, several molecules known to be activated in the inflammatory milieu or, on the other hand, having a role as inducers of an inflammatory response, are molecules of great interest on the molecular mechanisms of depression and others psychiatric diseases.

Congruent with previous studies on non-pregnant women with depressive symptoms (79-82), the most consistent finding of the present study was the significant association between elevated CRP levels and depressive symptoms during pregnancy. Pro-inflammatory markers, such as TNF- α , IL-1beta and IL-6 are released as response to stress or tissue damage, and they in turn induce the release of acute phase proteins, i.e. CRP, into the plasma. The molecular pathways through which these cytokines can

impact on the development of depressive symptoms involves the dysregulation of neurotransmitter synaptic availability of monoamines such as serotonin, noradrenaline and dopamine, as well as the metabolism of various amino acids such as tyrosine, tryptophan, phenylalanine and glutamate (83). Tryptophan (TRP) metabolism plays an important role in the mechanisms associated with the gut-brain axis (84). Specifically, the kynurenine pathway (KP) is responsible for more than 90% of TRP catabolism throughout the body, with indoleamine 2,3-dioxygenase (IDO), the key metabolic enzyme, being activated in the inflammatory environment, leading to the downstream production of a variety of neuroactive compounds. The remainder of TRP is metabolized to serotonin and indole (85). In parallel, dysregulation of TRP metabolites such as serotonin, quinolinic acid (QUIN), and kynurenic acid (KA) has been linked to depressive behavior in animal models as well as in humans. Specifically, IL-1 β and TNF- α may be responsible for the induction of p38 mitogen-activated protein kinase (MAPK), which in turn can increase the expression and function of serotonin reuptake pumps, resulting in decreased serotonin synaptic availability and subsequently in depressive-like behavior in experimental animal studies (86). Another biological mechanism that may underlie the association between inflammation and PPD onset includes the release of reactive oxygen or nitrogen species which in turn can decrease the availability of tetrahydrobiopterin (BH₄), a key enzyme co-factor in monoamine synthesis (87).

The present review also highlights the large heterogeneity of results regarding the role of different inflammatory markers in depression during different time periods. This can be at least partly explained by the window of exposure; compared to delivery and postpartum, pregnancy is a period of large HPA-axis and sex-steroid hormone changes, which may explain the robust findings of the identified studies focusing on

inflammatory markers during pregnancy (88). An earlier clinical trial (75) reported that the levels of IL-6 and its receptor (IL-6R) were significantly higher during early pregnancy than before delivery, and women who developed depressive symptoms in the early puerperium had significantly higher serum IL-6 and IL-6R concentrations than those without. However, the different timing of sampling, even the week of sampling, the different study designs (cross-sectional versus longitudinal, population-based vs. case-control, etc.), as well as the different power of each study and diversity of ethnicities among the study populations can also account for eventual differences in the results.

An important finding of the present review was the inclusion of longitudinal studies which assessed the role of inflammatory markers as predictive markers in depressive symptoms onset. In particular, six studies assessed biomarkers at some time during pregnancy in relation to depression during postpartum, showing a potential predictive role of TNF- α and IL-6 in the diagnosis of PPD (1, 3, 24, 70, 71, 75). Moreover, three studies with longitudinal design explored the predictive role of inflammatory markers assessed during delivery in relation to depression during postpartum (2, 66, 67). These results are congruent with a recent review reporting the predictive value of proinflammatory cytokines in the diagnosis of PPD during postpartum (89). In general, although longitudinal studies suggest that the relationship between depression and inflammation is characterized by complex bidirectional associations, existing, prospective, longitudinal research designs are still poorly equipped to investigate the dynamic interplay of depression and inflammation that unfolds over a relatively short time period (90).

Critical appraisal: strengths and limitations

The present study acknowledges that the systematic review of PPD epidemiology, especially on the role of inflammatory markers in PPD onset, is a rather challenging field of research mainly due to the large heterogeneity of available evidence and several inherent limitations of the individual studies. First, the definition of exposure and outcome among inflammation and depression is not always straightforward. Further, the large heterogeneity in assessment of the inflammatory markers is perhaps the most important methodological limitation of the studies. Markers of inflammation are a heterogeneous group of very different active components. The studies have often focused on different molecules and have even used different methods for their identification and quantification. In addition, the identified studies assessed the role of inflammatory markers in different time points, namely during pregnancy, delivery and postpartum, thus not readily allowing a quantitative synthesis of the results in the context of a meta-analysis. Further, even depression was assessed differently, with some studies using self-reports measures that often capture perinatal distress and not depression in particular, while other used clinical instruments used in psychiatric settings to set a diagnosis of major depression. This might account for some of the inconsistencies in results between the studies. Among other limitations, we excluded from this systematic review results of inflammatory markers related to quantification of immune cells as well as physical properties such as erythrocyte sedimentation rate (ESR). Moreover, mRNA and epigenetic studies were also excluded, as this work focused on protein level markers. In addition, it would be essential to account for confounding from potential co-exposure to multiple markers or even other molecules and hormones, in order to delineate unbiased associations, but this has not been possible in the overwhelming majority of evidence assessed herein.

Nonetheless, beyond these limitations, the present study followed a strict pre-registered protocol and systematically reviewed all available evidence regarding the association between different inflammatory markers at the protein level and peripartum depressive symptoms. In trying to synthesize the available evidence, we also grouped the results by window of exposure and type of study, and identified studies where inflammatory markers were tested for their predictive potential.

Conclusions and practical clinical implications

The present systematic review summarized the current evidence on the association of inflammatory markers and depressive symptoms during the peripartum period. Beyond potential limitations and biases, the findings of the present work provide evidence of increased pro-inflammatory markers among women with depressive symptoms. Further evidence from sufficiently powered studies that apply robust and preferably the same methods for assessment of inflammatory markers and PND symptoms, at specific and homogeneous time periods is needed; this could further enhance our understanding of the pathophysiology of PND with mechanistic studies, and shed light into potentially relevant molecular pathways that underlie these associations, in the hope of new possible treatments. Further work could point to the practical application of a panel of such biomarkers for the early identification of women at risk of developing PPD in order to use preventive interventions.

Funding

AS-F was supported by the Portuguese Foundation for Science and Technology and the Portuguese Ministry of Science, Technology and Higher Education, through the national funds, within the scope of the Transitory Disposition of the Decree No.

57/2016, of 29th of August, amended by Law No. 57/2017 of 19 July and previously through the fellowship grant SFRH/BPD/107732/2015.

This paper is part of the COST Action Riseup-PPD CA18138 and was supported by COST under COST Action Riseup-PPD CA18138 (Virtual Mobility Grant).

Acknowledgements:

The authors would like to thank Maria Karalexi, Pietro Gambadauro, Georgios Schoretsanitis and Andrea Hess Engström for help with appraisal of results, and Mariana Saraiva for support on title and abstract screening.

Authors declare no conflicts of interest.

Table 1. Cross-sectional and case-control studies on inflammatory biomarkers and depression

Reference	Country	Study design	Number of subjects	Socio-economic status/ethnicity	Delivery mode	Assesment of depression		Inflammatory protein markers				Results	Total quality score
						Instruments	Timepoint(s)	Biological fluid/hour of collection	Timepoint(s)	Dosage assessment technique	Inflammatory markers		
Pregnancy													
(34)	USA	Nested case-control (from a prospective cohort study)	T=462 (Ct=390, PND=72)	39.5% college graduate; 40.7% non-white race;	NR	Perinatal depression documented by the obstetric or the primary care provider in the electronic medical record (EMR) of the study institution.	Anytime across pregnancy	Plasma/NR	Average of three visits: 10, 18 and 26 gw	(1) Hs Multiplex Assay; (2) DuoSet ELISA	(1) IL-6, IL-10, CRP, IL-1 β , TNF- α , (2) CRP	NS	6
(42)	USA	Cross-sectional	T=187	87.2% \geq High school education; 87.7% reported income of \$34,315.2 \pm 31,431.2; 100% African American	NR	Depressive symptoms measured as CES-D total score; CES-D \geq 16 equate with symptoms of depression;	13.1-28.6 gw	Serum/NR	13.1-28.6 gw	(1) ELISA; (2) custom 4-plex assay	(1) hs-CRP, (2) IL-1 β , IL-6, IL-10 and TNF- α	(+) correlation of CES-D with IL-6 (p=.04) and IL-1 β (p=.03)	7
(43)	Finland	Cross-sectional (from a cohort study)	T=139	5.8% low education levels	NR	EPDS: continuous total sum score was used for the main analyses. Additional comparisons (high/low EPDS) with the cut-point 9/10.	24 gw	Serum/randomly through the office hours	24 gw	Bio-Plex Pro Human Cytokine 21- and 27-Plex Assay kits	IL-6, IL-10, TNF- α , IL-9, IL-5, IL-12, IL-13, IFN- γ , IL-4	(+) correlations between EPDS scores and four cytokines: IL-5 (p=.007), IL-9 (p=.011), IL-12 (p=.018), IL-13 (p=.029) and the IFN- γ /IL-4 ratio (p=.039).	6
(45)	USA	Cross-sectional	T=60	82% high school or less education; 63% annual family income < \$15,000; 57% African American	NR	Depressive symptoms measured as CES-D total score (clinical cut-off 16)	M=15 \pm 7.8 gw	Serum/9:30 am-1:30 pm	15 \pm 7.8 gw	Ultra sensitive multiplex kits	IL-6, TNF- α	NS	7
(35)	USA	Nested case-control (from a cohort study)	T=200 (Ct=100; depressed =100)	Caucasian: 81% in depressed group and 78% in Cts	NR	DSM-V diagnosis of depression (depressed group). Documented negative EPDS for Cts	Prior to pregnancy and confirmed during pregnancy	Serum/NR	11-14 gw (M=12.8 gw in Cts and 12.6 gw in depressed group)	(1) hs-ELISA; (2) Multiplex Assay	(1) IL-6, (2) TNF- α	\uparrow IL-6 (p=.03) and \uparrow TNF- α (p<.0001) levels in depressed vs Cts groups.	6
(46)	Thailand	Cross sectional	T=73 (Non-pregnant=24; pregnant no PND=25, pregnant+ PND=24)	Years of education: 17.8 \pm 1.3 Non-pregnant; 12.5 \pm 3.3 pregnant no PND; 12.0 \pm 4.3 pregnant + PND.	NR	EPDS to assess the diagnosis of perinatal depression (EPDS \geq 11 for depressed and EPDS \leq 2 for non-depressed) and HAM-D	3rd trimester (at the end of term) and 4-6 wks PP	Serum	3rd trimester (at the end of term)	(1) ELISA; (2) Atomic absorption spectrometric method; (3) latex immunoassay; (4) spectrophotometric method;	(1) assay of IgM/IgA responses to tryptophan + TRYCATS: Anthranilic acid, Xanthurenic acid, Quinolinic acid, Kynurenic acid, IgA Picolinic acid, 3-OH Kynurenine, Kynurenine, Quinaldic acid,	\downarrow IgA responses to anthranilic acid in PND vs pregnant no PND (p=.047).	8

											3-OH Anthranilic acid (2) zinc, (3) hs-CRP, and (4) haptoglobin		
(36)	Sweden	Case-control (substudy in the BASIC cohort study)	T=258 (Ct=160; Perinatal depressive disorder=59; Antidepressant treatment=39)	University education: Ct=84.4%, perinatal depressive disorder=67.8%, antidepressant treatment=74.4%	NR	(1) EPDS (psychophysiology sub-study EPDS \geq 13, cesarean EPDS \geq 17). (2) MINI and MADRS performed only in participants from the psychophysiology sub-study.	(1) 17 and 32 gw; (2) 35-39 gw	Plasma/9:30 am-1:00pm and morning before cesarean	Late pregnancy (35-39 gw) (n=205) and at morning before cesarean section (38w) (n=53)	Proseek Multiplex Inflammation I (based on proximity extension assay technology)	92 inflammatory proteins	↓23 inflammatory proteins in women with perinatal depression (p<.01) and women on SSRI treatment in comparison with Ct (p<.01): TRAIL, CSF1, CX3CL1, CST5, DNER, VEGFA, STAMPB, CD5, CD244, TNFRSF9, TNFB, IL10RB, CD40, IL15RA, hGDNF, ST1A1, CCL11, ADA, CCL25, uPA, AXIN1, SLAMF1, IL17C (-) significant correlations between the 23 molecules described above with depression symptoms severity (MADRS scores) at 36 gw as well as with EPDS scores in 17 and 32 gw (with the exception of AXIN1 and TNFRSF9 at 32 gw).	6
(37)	USA	Cross-sectional (from a prospective observational study)	T=117	NR	100% cesarean	IDS-SR30 \geq 18, MINI	Pre-cesarean	Plasma and CSF/NR	Pre-cesarean	Flow cytometry	IL-1 β , IFN- α , IFN- γ , TNF- α , MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-33.	↑ IL-1 β (95%CI 5.9-9148.5), ↑ IL-23 (95%CI, 1.7-294.5), ↑ IL-33 (95%CI 1.1-2.6) levels in the CSF have significant associations with increased odds of PND.	-
(38)	China (Taiwan)	Case-control	T=33 (Ct=16; PND=17)	Education years: Ct=16.8 \pm 1.0, PND=16.6 \pm 1.5	NR	DSM-IV diagnosis by MINI; EPDS \geq 12/13	16-28 gw	Plasma/9:00-10:00am	16-28 gw	(1) nephelometry immunoassay; (2) Multiplex assay	(1) CRP; (2) IL-6, IL-10 and TNF- α	↑ TNF- α levels in PND vs Ct groups (p=.016). (+) correlation between PND duration and TNF- α levels (p<.01)	6
(33)	USA	Cross-sectional	T=105	51.5% High school or less; 4.8% household income <\$4,999; 70.5% caucasian	NR	POMS-D continuous total sum score (7,6% met the protocol's screening criteria for possible clinical depression with a POMS-D score greater than 20)	16-26 gw (M=20 gw)	Plasma/mean time of day=11:25am	16-26 gw (M=20 gw)	12-plex assay	TNF- α , IFN- γ , IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, and IL-13	(-) correlations of POMS-D with IL-1 β (p<.05), IL-7 (p<.05) and TNF- α (p<.01). Hierarchical linear regression models: depression contributed to the levels of plasma cytokine IL-1 β , IL-7 and TNF- α .	6
(44)	USA	Cross-sectional	T=206	95.1% High school or less; 49.5% Mexican American	NR	Depressive symptoms defined as a CES-D	22-24 gw	Plasma/NR	22-24 gw	ELISA	IL-1RA	↑ IL-1RA levels in group with CES-D>20 in	8

		(from a prospective observational study)				score of >20.						comparison with CES-D<20 group (p=.018).	
(91)	USA	Cross-sectional (from a cohort study)	T=72	African-american; 60% unemployed; 49% high school level or less	NR	CES-D continuous total sum score (CES-D ≥ 16 frequently used to indicate a positive screen for depression)	14-17 gw	Plasma/NR	14-17 gw	BioPlex Pro 17-plex kit.	IL-1β, TNF-α, IL-6, IL-8, IL-12, IL-17, IFN-γ	(+) correlations between CES-D scores and IL-8 (p=.008).	6
(40)	NR	Cross-sectional	T= 44 (Ct=14; PMMD=30)		NR	PMMD monitored by consultation psychiatricservice. The severity of depressive symptoms was measured by the EPDS.	M= 32.9 ± 4.18 gw	Plasma/ Late Morning	M= 32.9; SD=4.18 gw	ELISA kit	ERVWE1	NS	7
(39)	Italy	Cross-sectional study	T= 79 women (20 with PND+ TRAUMA, ii) 19 with PND + no-TRAUMA, iii) 20 HV pregnant; iv) 20 HV non-pregnant	Years of Education: No trauma=13.0±3.3; Trauma=14.5±2.9; HVpregnancy=14.0±3.9); Unemployed: No trauma= 10.5%; Trauma =25%; HVpregnancy=68.8%	NR	Diagnosis of PND was made by clinical interview according to the DSM-V criteria. The severity of current depressive symptoms was assessed by EPDS (EPDS≥12 for clinically relevant PND)	22-24 gw	Serum/8:00 and 10:00 a.m	22-24 gw	(1) NR; (2) ELISA	1) CRP; 2) TNF-α and IL-6	↑ CRP in the PND + no-TRAUMA group compared to the HV pregnant group;	6
Postpartum													
(57)	USA	Cross-sectional (from a longitudinal study)	T=69	Annual household income <\$15,000: 37,5% African American group and 18.9% in White group. High school graduate or less: 15.6% African American group and 27.0% in White group. African American (n = 32) and White (n = 37)	NR	CES-D continuous total sum score	7-10 wks PP	Serum and LPS-stimulated PBMCs culture/NR	7-10 wks PP	(1) single spot ultrasensitive ELISA; (2) multiplex assay	Serum; (1) IL-6; (2) TNF-α and IL-8 <u>LPS-stimulated PBMCs</u> ; (2) IL-6, TNF-α, IL-8 and IL-1β	Among African American women, controlling for BMI, (+) correlation between stimulated IL-6 (p<.01), IL-8 (p<.01) and TNF-α (p=.02) and CES-D depressed mood subscale.	8
(55)	USA	Cross-sectional (from a RCT study)	T=56 (n=33 for hsIL-6 ELISA)	23.2% lower SE class; 92.9% Caucasian	NR	(1) HRSD≥15 and (2) clinical interview including SCID-IV (if HRSD≥15 twice within the following 7-day period to identify a depression recurrence).	(1) 2,3,4,6,8,11,14 and 17 wks PP;	Plasma/NR	2, 3, or 4 wks PP	hsELISA	hsIL-6	NS (for risk depression recurrence)	7
(58)	China	Cross-sectional	T=10 (Ct=8; PPD=2)	NR	NR	patients with PPD provided by medical patterns	within the 4 weeks period of giving birth	Plasma/NR	within the 4 weeks period of giving birth	Ultrasensitive Lab-on-chips (LOC) device and ELISA	IL-2, IL-6, IL-8 and TNF-α	↑ IL-2 and ↑ IL-8 levels in PPD compared to Ct group (no statistical information is reported)	2
(63)	USA	Cross-sectional	T=181	Income <\$10,000: 13.6% breastfeeders group and 39.4% formula feeders	NR	POMS-D continuous total sum score	between 4-6 wks PP (M=5.2 wks)	Serum/8:00-11:00 am	between 4-6 wks PP (M=5.2 wks)	ELISA	IFN-γ and IL-10	(-) correlation between POMS-D and INF-γ only in the formula feeders	8

				group. White race: 89.8% breastfeeders group and 73.4% formula feeders group.								(p<.05).	
(64)	USA	Cross-sectional (secondary analysis)	T=199 (depressed n=25)	Depressed mothers had lower income in comparison with non-depressed women (p<.06)	NR	POMS-D ≥21 (depressed mothers were categorized as those with scores in the highest decile on the POMS-D scale)	4-6 wks PP (M=5.3 wks PP)	Serum and ex-vivo whole blood culture supernatant/ 8:00-11:00 am	4-6 wks PP (M=5.3 wks PP)	ELISA	IFN-γ, IL-6 IL-10	↓ serum IFN-γ (p<.001), ↓IFN-γ/IL-10 ratio in both serum (p<.04) and whole blood culture supernatants (p<.009) in depressed in comparison with not-depressed.	6
(62)	Iran	Case-control	T=62 (Cts=30; MDD=10; minor depression =22)	NR	NR	a psychiatrist used DSM-IV-TR to diagnose major and minor depression.	NR	Serum/NR	immediately after parturition	single radial immunodiffusion	IgG, IgM and IgA and complements C3 and C4	↑IgG levels in MDD (p=.026) compared with minor depression	6
(52)	USA	Cross-sectional	T=165 (Cts=60; depressive episode with peripartum onset=87; 18 displayed depression but did not fulfill the time criteria for peripartum-onset depression defined by DSM-5).	Unemployed: Cts=38%; Depressive episode with peripartum onset=37%	NR	EPDS total score; clinical interview SCID-5 for diagnosis of depressive episode with peripartum onset	8 wks PP (6-12 wks PP)	Plasma/9:00 am-12:00 pm	8 wks PP (6-12 wks PP)	(1) MesoScale Discovery platform; (2) HPLC; (3) GC-MS; (4) UPLC-MS/MS	(1) IL-1β, IL-2, IL-6, IL-8, IL-10, and TNF-α (2) Tryptophan, Kynurenine; (3) quinolinic acid (4) serotonin, kynurenic acid and nicotinic acid	↑IL-6, ↑IL-8 and ↓serotonin, ↓IL-2 and ↓quinolinic acid were associated with ↑ risk of PPD (OR _{IL-6} =3.0, p=.007; OR _{IL-8} =3.32, p=.009, per pg/ml increase; OR _{serotonin} =1.43, p=.016, per nM decrease; OR _{IL-2} =2.34, p=.002, per pg/ml decrease; OR _{quinolinic acid} =4.48, p=.014, per nM decrease) and ↑ depressive symptoms (IL-6: p=.022; IL-8: p=.006; serotonin: p=.003; IL-2: p=.005; quinolinic acid: p=.022) ↑kynurenine/serotonin ratio was associated with an increased risk for PPD (OR = 1.35 per unit increase, p=.038) and ↓serotonin/kynurenine ratio was associated with ↑EPDS score (p=.009).	7
(61)	Japan	Cross-sectional	T=129 breastfeeding mothers	96.1% high social support; 9 or less years of education: 1.6%	NR	EPDS ≥9 as having postpartum depression.	3 mo PP	Breast milk/65.9% at 12:00-2:00 pm	3 mo PP	ELISA	TGF-β2	↑TGF-β2 in mothers with depression than mothers without depression (p=.02); depressed mothers had a 3.11-fold (95% CI: 1.03–9.37) higher likelihood to have ↑TGF-β2 levels in their breast milk.	8
(59)	Sweden	Cross-sectional	T=64 (preterm group=27;	Low annual income (<115,000 SEK); preterm=0%,	NR	Semi-structured interview. Descriptions of	Within 5 days after delivery	Serum/NR	During labor	Multiplex assay	IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12	Pre-term group: (+) correlation between IL-8 and depressive	6

			term group=37)	term=10.8%. Secondary school: preterm=51.8%, term=40.5%.		continuous depressed mood were considered as depressive symptoms.					p70, IL-13, IL-17, IL-18 and IFN- γ	symptoms (p<.01)	
(56)	USA	Cross-sectional	T=119	Income mean \$18,000 \pm \$6,000. 84% Caucasian	NR	POMS-D total score (cutoff score of 25 above which triggered a referral to a mental health professional.)	4-6 wks PP (M=4.5 \pm 2.3)	Morning hindmilk/pick up visit before 11:30 am	4-6 wks PP (M=4.5 \pm 2.3)	ELISA	IgA	NS	9
(60)	USA	Cross-sectional (from multicenter urban birth cohort study)	T=469	40% less than high school education. 70% annual income <\$15,000. 73% African American	NR	EPDS total score (EPDS \geq 12 indicated a need for further mental health evaluation)	89% at 12 mo PP, 8% at 24 mo PP and 3% at 36 mo PP	PBMC cells culture ex-vivo stimulated/NR	89% at 12 mo PP, 8% at 24 mo PP and 3% at 36 mo PP	Multiplex ELISA assay	Innate Stimuli: IFN- α , IFN- γ , IL-10, IL-12p40, TNF- α and IL-8. Adaptive and Mitogenic Stimuli: IFN- γ , IL-10, IL-13, IL-4 and IL-5	(-) correlations between depression and innate immune responses, namely, CpG-induced TNF- α (p=.02), RSV induced IL-8 (p < .05), and LPS induced IFN- γ (p=.02). (-) correlations between depression and adaptive immune responses, namely, several DM-induced cytokines (IL-4, IL-5, IL-10, and IL-13; p<.05), and CR-induced IL-10 (p=.01).	7

Note: ADA: Adenosine deaminase; AXIN1: Axin 1; BMI: Body Mass Index; CES-D: Center for Epidemiological Studies Depression Scale; CCL: C-C Motif Chemokine Ligand; CpG: cytosine-phosphate-guanine; CR: Cockroach extract; CRP: C-reactive protein; CSF: cerebrospinal fluid; CSF1: colony stimulating factor 1; CST5: Cystatin D; Cts: Controls; CX3CL1: C-X3-C Motif Chemokine Ligand 1; DM: Dust mite* extract (* D. pteronyssinus); DNER: Delta/Notch Like EGF Repeat Containing; DSM: Diagnostic and Statistical Manual of Mental Disorders; ELISA: enzyme-linked immunosorbent assay; EPDS: Edinburgh Postnatal Depression Scale; ERVWE1: Human Endogenous Retrovirus W EnvC7-1 Envelope Protein; GC-MC: Gas chromatography-mass spectrometry; gw: gestational weeks; HAM-D or HDRS: Hamilton Depression Rating Scale; hGDNF: Glial cell line-derived neurotrophic factor; HPLC: High performance liquid chromatography; hs: high-sensitivity; HV: Healthy volunteers; IDS-SR30: Inventory of Depressive Symptomatology Self-Rated; IFN- α : Interferon alpha; IFN- γ : Interferon gamma; Ig: Immunoglobulins; IL-: Interleukin-; IL-1 β : Interleukin 1 beta; IL-1RA: Interleukin 1 receptor antagonist; IL10RB: Interleukin 10 Receptor Subunit Beta; IL15RA: Interleukin 15 Receptor Subunit Alpha; LPS: Lipopolysaccharides; M: Mean; MADRS: Montgomery Asberg Depression Rating Scale; MCP-1: monocyte chemotactic protein 1; MDD: Major Depressive Disorder; MIF: Macrophage migration inhibitory factor; MINI: The Mini International Neuropsychiatric Interview; mo: months; ng/ml: nanogram per milliliter; nM: nanomolar; NR: not reported; NS: not significant results; PBMCs: Human peripheral blood mononuclear cells; PMMD: Perinatal Major Depressive Disorder; PND: Perinatal depression; POMS-D: Profile of Mood States-depression-dejection scale; PP: postpartum; PPD: Postpartum depression; RCT: Randomized Control Trial; RSV: Respiratory syncytial virus; SCI: structured clinical interview; SCID: Structured Clinical Interview for DSM; SE: Socio-economic; SLAMF1: Signaling Lymphocytic Activation Molecule Family Member 1; STAMPB: STAM Binding Protein; ST1A1: Sulfotransferase Family 1A Member 1u; T: Total; TGF- β 2: Transforming growth factor-beta 2; TNF- α : Tumor necrosis factor alfa; TNFB: Tumor necrosis factor B; TNFRSF9: TNF Receptor Superfamily Member 9; TRAIL: TNF-related apoptosis-inducing ligand; uPA: urokinase-type plasminogen activator; UPLC-MS/MS: Ultra-high performance liquid chromatography, coupled to tandem mass spectrometry; VEGFA: Vascular Endothelial Growth Factor A; vs: versus; wks: weeks; \uparrow : Increase; \downarrow : Decrease; (+): positive; (-): negative.

IL-6, IL-10, and TNF- α were chosen as they are the most relevant cytokines studied in the field of depression research and represent both proinflammatory (IL-6 and TNF- α) and anti-inflammatory cytokines (IL-10)

Table 2. Longitudinal studies of inflammatory biomarkers and depression

Reference	Country	Study design	Number of subjects	Socio-economic status/ethnicity	Delivery mode	Assessment of depression		Inflammatory protein markers			Results	Total quality score	
						Instruments	Timepoint(s)	Biological fluid/hour of collection	Timepoint(s)	Dosage assessment technique			Inflammatory markers
Pregnancy													
(74)	Canada	Longitudinal	T=27	48% had some high school education; 65% annual family income <\$40,000.	NR	PHQ-9 continuous scores to represent symptom severity.	T1 (7-10 gw), T2 (16-20 gw)	Serum/08:30 am-12:30am	T1 (7-10 gw), T2 (16-20 gw)	ELISA	CRP, hsIL-6 and hsTNF- α	The inflammatory markers at T1 and depressive symptoms at T1 and T2 were moderately correlated ($r=0.44-0.53$). \uparrow depressive symptoms at T1 predict \uparrow CRP levels ($p=0.03$) and \uparrow TNF- α levels ($p=0.00$) at T2. \uparrow depressive symptoms at T2 predict \uparrow CRP levels ($p=0.01$), \uparrow IL-6 levels ($p=0.04$) and \uparrow TNF- α levels ($p=0.047$) at T2. There was a significant association between increase in depressive symptoms from T1 to T2 and IL-6 levels ($p<.006$).	5
(92)	USA	Longitudinal (from a prospective cohort study)	T=145	20.7% in complete high school; 46.2% African American	19% cesarean	EPDS continuous total score, SCID (Clinical diagnoses of current depression and history of depressive episodes)	18 and 32 gw	Serum/8:00am-14:00pm; 14 samples were collected between 14:00-16:00pm	18 and 32 gw	hsELISA	IL-6 and TNF- α	NS	6
(93)	Finland	Longitudinal (from a Cohort Study PREDO)	T=295 (sample with depressive symptoms reported during pregnancy)	NR	NR	CES-D (continuous variable and as a binary variable indicating probable clinical depression-CES-D ≥ 16).	2x wk until 38–39 gw or delivery.	Plasma/ 19:00 PM-21:00 PM	median 13, 19, 27 gw	CRP immunoturbidometric assay	hsCRP	\uparrow hsCRP levels in those with compared to those without depressive symptoms during pregnancy (95% CI 0.17–1.88 mg/L)	8
(41)	Ireland	Cohort study	T=209 healthy pregnant women (n = 104 with no IBS)	NR	NR	EPDS (Lower quartile (PSS — 7.5; STAI — 23.3; EPDS — 2.5) and upper quartile scores (PSS — 17; STAI — 40; EPDS — 9.5) were used as cutoffs to define low- (<25th percentile), moderate- (25th to <75th percentile), and high- (≥ 75 th percentile) scoring groups for each of the	15 \pm 1 (visit 1) and 20 \pm 1 (visit 2) gws	Plasma + Serum / before 12 pm on the morning of each visit	15 \pm 1 (visit 1) and 20 \pm 1 (visit 2) wks' gestation	(1) Multiplex Assay; (2) HPLC	1) IFN- γ , TNF- α , IL-6, IL-18, IL-8, IP-10, MCP-1, SDF-1 α , MIF and CRP; 2) TRP and KYN	\uparrow CRP levels in the high-scoring group vs moderate ($p=0.026$) and low scorers ($p=0.048$). \uparrow TNF- α in the moderate-scoring group vs the low-scoring group ($p=0.006$). \downarrow IL-8 levels at 20 gw vs at 15 gw for moderate- ($p=0.001$) and high-scoring groups ($p=0.035$). (-) correlation between IL-8 levels and EPDS scores at 20 gw (NS in the adjusted model)	7

						psychological evaluations.							
Pregnancy and Postpartum													
(70)	USA	Longitudinal	152 women	80% married 76% Caucasian 24.4% low income	100% vaginal delivery	Symptomatic of PPD (EPDS \geq 10)	32-36 gw, 7d, 14d \pm 48-h, 1, 2, 3, 6 mo (\pm 1wk) PP	Plasma/NR	32-36 gw, 7d, 14d \pm 48-h, 1, 2, 3, 6 mo (\pm 1w) PP	Human Pro-inflammatory Ultra-Sensitive assay and quantitative multiplex array technology (not discriminated)	IL-6, IL-1 β , TNF- α , IL-8, IFN- γ , IL-10.	\downarrow TNF- α in PPD vs not depressed at any time (p<.05) (results replicated over time) \uparrow day 14 IL-8/IL-10 ratio among PPD symptomatic vs. non-symptomatic (p=.006)	6
(47)*	Japan	Longitudinal	132 pregnant women (ND=62, PD=15, TG=22; CD=33)	NR	NR	EPDS (ND group=EPDS<8/9 all timepoints; PD group=EPDS>8/9 only at the 1 mo PP period; TG group=EPDS>8/9 only during pregnancy; CD group=EDPS>8/9 during pregnancy and PP.	before 25 gw and ~36 gw; 1mo PP	Plasma /NR	before and 1 mo after delivery	HPLC	TRP, KYN, KA, AA, 3HK and 3HAA.	\uparrow KYN and \uparrow KA (p<.01) and \uparrow KYN/TRP and \uparrow KA/KYN ratio (p<.05) in PD group vs ND group during pregnancy period. \downarrow 3HAA PD vs ND group in PP period (p<.05). \downarrow KYN ratio (p<.01) and \downarrow KYN/TRP ratio (p<.01) (during PP period to that during pregnancy) in PD group vs ND group. (+) correlations between KYN (p<.01), KA (p<.05) levels and KYN/TRP ratio (p<.05) during pregnancy and EPDS score during postnatal period. (-) correlations between 3HAA levels (p<.05) and EPDS score during postnatal period.	5
(94)	USA	Longitudinal cohort study	171 pregnant women (81 African American group, 90 non-African American group)	53% single	34% cesarian section	EPDS; SCID - current diagnoses of depression	18 gw, 32 gw, 6 w PP, 6 mo PP	Serum	18 gw, 32 gw, 6 wks, 6 mo pp	hs ELISA	IL-6, TNF- α	NS	5
(48)	Belgium	Longitudinal	98 healthy pregnant females	NR	NR	(1) BDI, (2) SCID diagnoses of PPD	(1) 3-6 days before the anticipated delivery + 1 and 3 days PP; (2) 6-10 m PP	(1) Plasma; (2) Serum	08:00 am (+/- 30 min) 3-6 days before the anticipated date of delivery and 1 and 3 days after delivery	(1) HPLC, (2) ELISA	(1) TRP and KYN; (2) IL-6, IL-8, LIF-R	\uparrow KYN (p=.01) and \uparrow K/T quotient (p=.01) in BDI responders vs. nonresponders 3d after delivery \uparrow in the K/T quotient over time in BDI responders (p=.0005) vs. NS changes overtime in non-responders.	7
(65)	Belgium	Longitudinal	71 participants, (15.5% major PPD, 8.4%	NR	NR	(1) ZDS; (2) SCID diagnoses of PP depression	(1) 3-5 days before the anticipated date of delivery and 1 and 3 days after delivery; (2)	Serum	08:00 am (+/- 30 min) 3-5 days before the anticipated	ELISA	CC16	\downarrow serum CC16 levels (p=.002) in women with PPD vs those without postpartum depression.	8

			minor PPD)				6-10 m PP		date of delivery and 1 and 3 days after delivery				
(49)	Belgium	Longitudinal	98 healthy pregnant females	NR	NR	(1) ZDS; (2) SCID diagnoses of PP depression	(1) 3-5 days before the anticipated date of delivery and 1 and 3 days after delivery; (2) 6-10 m PP	Plasma	08:00 am (+/- 30 min) 3-5 days before the anticipated date of delivery and 1 and 3 days after delivery	HPLC	Tryptophan	NS	7
(24)*	USA	Longitudinal (secondary analysis)	T=63	19.4% high school or less. 64.5% White race	NR	EPDS≥12	At baseline (between 28-34 gws M=32,5 gws), 3 mo PP, 6 mo PP	Serum/8:00 am-5:00 pm	At baseline (between 28-34 gws M=32,5 gws), 3 mo PP, 6 mo PP	Multiplex assay	TNF-α, IL-6, IL-1β and CRP	↑TNF-α associated with ↓EPDS score (95% CI [-1.84,-.036]), adjusted for confounders (days since delivery, time of blood draw and antidepressant treatment or potentially anti-inflammatory medications and self-reported level of hardship)	6
(71)	USA	Longitudinal	151 pregnant women	78.1% Caucasian 24.5% low income	100% vaginal	EPDS	32-36 gw, 1 w PP, 2 w PP, 1 mo PP, 2 mo PP, 3 mo PP and 6 mo PP (7 total)	Blood	32-36 gw, 1 w PP, 2 w PP, 1 mo PP, 2 mo PP, 3 mo PP and 6 mo PP (7 total)	NR	IL-6, TNF-α, IL-10	↑TNF-α associated with ↓EPDS (95% CI = [-1.24,-0.11])	6
(95)	Belgium	Longitudinal	91 healthy pregnant women,	NR	100% vaginal	(1) ZDS; (2) SCID diagnoses of PP depression	3-5 days before the anticipated delivery, 1 day PP and 3 days PP; (2) 6-10 m PP	serum	3-5 days before the anticipated delivery, 1 day PP and 3 days PP	ELISA	IL-6, IL-6R, sgp130, IL-1RA and LIFR	↑IL-6 (p=.027) and ↑IL-6R (p<.001) in ZDS reactors vs. non-reactors, before delivery (p=.006), and 1d (p=.001) and 3d (p=.002) PP; ↑IL-6*IL-6R values in reactors vs. non-reactors (p<.001), 1d (p=.001) and 3d (p=.01) after delivery	6
(53)	USA	Longitudinal	28 pregnant women (14 healthy controls, 14 depressed group = EPDS ≥ 10)	Less than \$20,000 14.3% (healthy) and 28.6% (depressed); 50% Caucasian and 42.9% African American in both groups; less than high school 7.1% (healthy) and 21.4% (depressed)	Vaginal: 85.7% Healthys. and 70% Depressed	EPDS	8-12 gw	Plasma	8-12 gw (visit 1), 24-28 gw (visit 2), and 6-8 w PP (visit 3)	(1) limulus amebocyte lysate QCL-1000 kit; (2) Bio-Plex Pro™ Human Chemokine Panel	(1) LPS; (2) TNF-α, IL-6, IL-1β and MCP/CCL2	↑LPS at 8-12 gw (visit1) (p=.007), ↑TNF-α and MCP/CCL2 at 8-12 gw (p=.02 and p=.04, respectively) and ↑IL-6 at 24-28 gw (visit2) (p=.02) in depressive subjects vs. healthy group, even when BMI, age and race were controlled; NS differences between depressed vs. healthy women for IL-6 and IL-1β at visit 1	8
(25)*	Sweden	Nested case-control (from BASIC cohort study)	T=291 (Cts=228; PP depressive	Primary/Secondary School: Cts=19.7% and	Vaginal or Vacuum Extraction: Cts=	EPDS≥14 and MINI interview	8 wks PP	Plasma/most at morning	Days from blood sampling to delivery:	Multiplex extension assay	74 of 92 inflammatory markers (16 excluded for	↑STAM-BP (p=.002), ↑Axin-1 (p=.004), ↑ADA (p=.001), ↑ST1A1 (p=.04) and ↑IL-10 (p=.029) NPX values in Cts vs	6

			symptoms =63)	PP depressive symptoms =30.2%	61.4%, PP depressive symptoms =52.4%				Cts=14.0 (median), 15.0 (IQR);		being below LOD for >50% of the samples and 2 for technical problems)	depressive symptoms groups after adjusting for multiple testing. ↑STAM-BP (p=.07), ↑Axi1 (p=.007), ↑ADA (p=.020), ↑ST1A1 (p=.026), ↑SIRT2 (p=.016), ↑CASP8 (p=.013), ↑IL-10 (p=.039) and ↑MCP2 (p=.015) NPX values in Cts vs PP depressive symptoms group.	
(72)	USA	Longitudinal	51 women	black: more depressed (58%), less depressed (42%), hispanic: more depressed (42%), less depressed (53%), partner: more depressed (58%), less depressed (72%)	Pre-term birth: more depressed (17%), less depressed (16%)	BDI scores (≤ 9 vs. >9)	T1: 8-20 gw (M= 14.5, SD= 3.1; T2: 26 gw (SD+1); T3= 35 gw (SD=0.8); T4: 6wks pp; T5: 24 wks pp	Serum	T1: 8-20 gw (M= 14.5, SD= 3.1; T2: 26 gw (SD+1); T3= 35 gw (SD=0.8); T4: 6wks pp; T5: 24 wks pp	Bead-based ELISA	23 cytokines	(↑)IL-6 and CCL3 at T3 (IL-6:p<.001; CCL3: p<.001), (↑) IL-15 at T1 and T3 (p=.027 and p=.003, respectively), (↑) G-CSF at (T4) PP1 (p=.002) on more depressed vs. less depressed woman Slope of change for cytokines (IL-6, CCL3, IL-15, G-CSF) are different between depressed and non-depressed women.	7
(69)	Thailand	Longitudinal	24 non pregnant women, 25 non-depression pregnant women, 23 pregnant with depression	education in years: non pregnant =7.8 (1,3), pregnant no depression= 12, 5(3,3), pregnant depression=11, 9(4,3); Single/married/separated: non pregnant = 21/3/0, pregnant no depression= 4/18/3, pregnant depression= 4/17/2	NR	EPDS ≥11 categorized as "prenatal depression", BDI, HAM-D, MINI-Thai version	3rd pregnancy trimester and 4-6 w PP	Plasma	Third trimester and 4-6 w PP	hs CRP Vario assay	hs-CRP	(+) correlation between CRP and prenatal EPDS (p=.007), HAM-D (p=.013), and BDI (p=.001)	6
(50) overlap sample with (51)	USA	Longitudinal	29 pregnant women	African American (85%) and single (74%)	NR	SIGH-SAD	T1(35–38 gw), T2 (1–5 d PP), T3 (5–6 wks PP)	Serum	T1(35–38 gw), T2 (1–5 d PP), T3 (5–6 wks PP)	(1) ELISA (2) HPLC on reversed phase	(1) CRP, IL-6, (2) TRP, KYN and KYN/TRP	(+) correlation between prepartum CRP and SIGH-SAD atypical score (p=.007) (-) correlation between early pp CRP and SIGH-SAD atypical score (p=.047)	6
(73)	USA	Longitudinal	46 pregnant women (only 12)	58.3% African American, 66.7% high school or higher	50% C-section	CES-D	T1 (>36 gw); T2 (4-6 wks PP)	Serum	T1 (>36 gw); T2 (4-6 wks PP)	Bioplex Cytokine Assay	L-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17,	(+) correlation between prenatal depressive symptoms and MIP-1β (p<.05)	4

			have completed surveys and blood samples at both time points)	education, 16.7% married or partnered, 66.7% were single never married, 25% were full-time employed and 3.3% were part-time employed							MIP-1 α , GM-CSF, IFN- γ , MCP-1, MIP-1 β , and TNF- α		
(54)	Germany	longitudinal	100 pregnant woman	Married or solid partnership (98.6 %);	NR	MARDS and EPDS	34 gw, 38 gw, 3 days PP, 7 wks PP, 6 mo PP	Serum/8-10 am	34 gw, 38 gw, 3 days PP, 7 wks PP, 6 mo PP	ELISA	neopterin	↑ postnatal neopterin levels in mothers with postnatal depressive symptoms vs. mothers without postnatal depressive symptoms (p=0.49) using MARDS.	7
(51) overlap sample with (50)	USA	longitudinal	27 women	African American (85%), never married (74%), education: less than high school (19%), high school graduate (48%)	NR	SIGH-SAD	35–38 gw ; 1–5 days PP, 5–6 wks PP	Serum/NR	35–38 gw ; 1–5 days PP, 5–6 wks PP	(1) Two antibody ELISAs; (2) HPLC on reversed phase	(1) CRP, IL-6, (2) TRP, KYN and KYN/TRP	(+) correlations between CRP and prepartum atypical depression scores (p=.005) as well in total depression score. (-) correlations between CRP total and atypical depression scores in the early PP. (-) correlations between TRP and total depression score in the prepartum period.	6
(1)*	Canada	Longitudinal	33 healthy pregnant women	working full-time (80.7%); with university degree (51.7%); Married/comm on (100%)	NR	EPDS	3rd trimester (M=30.1, SD=4.1) and 12 w PP (M=13.5, SD=1.9)	Serum/8:15 am - 3:30 pm	3rd trimester (M=30.1, SD=4.1) and 12 w PP (M=13.5, SD=1.9)	ELISA	IL-6, IL-10, TNF- α and CRP	↓ IL-6 (p=.025), IL-10 (p=.006) at 3rd trim predict ↑ PP EPDS scores	7
(96)*	Sweden	Case-control	347 women	NR	NR	EPDS	5 days PP, 6 wks PP and 6 mo PP	Serum/NR	Before delivery	ELISA	IL-6	NS	4
(3)*	USA	Longitudinal	T=114	Caucasian: 47.4%; 100% high school level or above; 36% income ≤\$15,000.	NR	SCID; EPDS (risk of significant depressive symptoms - binary outcome: EPDS≥13).	1st, 2nd, and 3rd trimester and PP	Plasma/ 9:00 am-12:00 am)	1st, 2nd, and 3rd trimester and PP	(1) Multiplex assay; (2) HPLC	(1) IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF- α (2) Kyn, Trp	↑IL-6 levels were associated with ↑EPDS scores (p=.012) and risk of significant depressive symptoms (p=.013). ↑IL-1 β levels were associated with ↑EPDS scores (p=.021) and risk of significant depressive symptoms (p=.010). IL-6, KYN and Kyn/Trp ratio in the 2nd trimester showed >95% chance of being (+) associated with EPDS scores and risk of significant depressive symptoms in the 3rd trimester.	7
(4)*	Italia	Longitudinal (from a Cohort study EDI)&	T=110	89.4% high school level or above 94.8% middle-high class	19 caesarean sections; 33 labor inductions	EPDS	34-36 gw, 2 days PP, 3 mo PP, 12 mo PP	Serum/NR	34-36 gw	(1) Quantikine hs ELISA kits; (2) HPLC system	(1) IL-6, (2) Trp, Kyn	Adjusting for maternal age, ↑ prenatal Kyn levels were associated with ↓ prenatal EPDS (p=.03) ↓Trp levels, ↑ IL-6 levels were associated with ↑ prenatal EPDS	7

													(p=04) and with the change in EPDS from pregnancy to all PP time-points (ps=04). ↓ Kyn/Trp ratio levels, ↑ IL-6 levels were associated with ↑ EPDS at delivery (p=05) and 12 mo PP (p=004), and with the change in EPDS from pregnancy to 12 mo PP (p=0.048). ↑ Kyn/Trp ratio levels, ↑ IL-6 levels were associated with a ↓ in EPDS from pregnancy to 3 (p=0.03) and 12 (p=0.014) mo PP.	
(76)	Italia	Longitudinal (from a Cohort study EDI)&	T=110	89.4% high school level or above 94.8% middle-high class	NR	EPDS	34-36 gw; n=89 re-evaluated at average 52±19.7 hours after delivery	Serum/Morning and Afternoon	34-36 gw; average 52 hours after delivery	Quantikine hs ELISA	IL-6, CRP	↑ prenatal IL-6 levels with every 1-point prenatal EPDS increase (p=04).	7	
Postpartum														
(2)*	Greece	Longitudinal	T=56	100% native Greek	70.97% Caesarian section	EPDS≥11	1 st wk (day 4) and 6 th wks PP	(1) Serum (n=56) and (2) CSF (n=33)/NR	(1) early in labor; (2) right before epidural analgesia was infused	ELISA	IL-6 and TNF-α	(+) correlations between CSF TNF-α and IL-6 as well as serum TNF-α levels with EPDS scores in early puerperium. 1st wk PP: ↑CSF IL-6 (p=039*); ↑Serum TNF-α (p=055*) and ↑CSF TNF-α (p=009*) were predictors of ↑EPDS. 6th wk PP: ↑CSF IL-6 (p=012*) and ↑CSF TNF-α (p=072*) were predictors of ↑EPDS. *statistical significance (p<.100)	6	
(68)*	USA	Longitudinal (secondary analysis)	T=26	92% white	100% vaginal birth	CES-D≥11 (36% were identified as demonstrating symptoms of depression on 28 day PP)	28 days PP	Urine/9:00-10:00 am (home visits)	0 (within 24 hr of giving birth), 7, 14 and 28 days PP	ELISAs	IL-6, IL-1β	women with depressive symptoms on Day 28 had ↑ IL-1β levels on day 14 PP compared to women without symptoms of depression (p=045)	6	
(66) (reported also in cross-sectional table)	China	Longitudinal (from Cohort study)	T=296 (PPD=45)	33.8% low/middle family's socio-professional category. 60.1% high school or less. 92.9% Han	59.5% assisted delivery (vacuum extraction or cesarean delivery)	EPDS≥12	within 6-mo after deliver	Serum/7:00-8:00 am	Within 48 hours of delivery	(1) enzyme cycling method (2) ELISA	hs-CRP, (2) IL-6	↑hs-CRP levels and ↑IL-6 levels in PPD group versus non-depressed (p<.0001). (+) correlation between hs-CRP and EPDS score (p=0001) hs-CRP independent predictor of PPD (95% CI 4.96-30.12) (+) correlation between IL-6 and EPDS score (p=0001) IL-6 independent predictor of PPD (95% CI 3.15-18.77)	8	
(67)*	Sweden	Nested case-control (from BASIC cohort study)	T=169 (Cts=107; PPD-symptoms group=62)	parental leave/sick leave/unemployed: Cts=2.8%; PPD-symptoms group=12.9%. University/college	Cesarean: Cts=19.6%, PPD-symptoms =19.6%	EPDS ≥ 12 and/or MINI interview (taking antidepressants was also used to identify cases)	6 or 8 wks PP	Plasma/8:00 am-15:00 pm	Days from delivery (M±SD): Cts=69.5±9.7 ; PPD-symptoms: 67.8±11.1	Multiplex extension assay	70 of 92 inflammatory markers (21 excluded for not having normalized protein	↑TRANCE (penalized OR=1.20), ↑HGF (penalized OR=1.17), ↑IL-18 (penalized OR=1.06), ↑FGF-23 (penalized OR=1.25) and ↑CXCL1 (penalized OR=1.11) in woman with PPD symptoms vs Ct	6 (2018 Excel)	

				ge: Cts=85.0%; PPD-symptoms group=80.6%							expression for >50% of the participants and 1 for technical problems)		
(97)	USA	Longitudinal (secondary analysis from a randomized trial)	T=35	NR	NR	SIGH-ADS ₂₉	baseline (study entry), study exit (4-8 wks post- study entry)	Serum/NR	baseline (study entry), study exit (4- 8 wks post- study entry)	Latex particle enhanced immunoturbidime tric assay	CRP	NS	6

Note: 3HAA: 3-hydroxyanthranilic acid; 3HK: 3-hydroxykynurenine(3HK); AA: anthranilic acid; ADA: Adenosine deaminase; AXIN1: Axin 1; BDI: Beck's Depression Inventory; BMI: Body Mass Index; CASP8: Caspase 8; CC16: Clara Cell Protein; CD: Continuous depressive group; CES-D: Center for Epidemiological Studies Depression Scale; CCL: chemokine (C-C motif) ligand; CRP: C-reactive protein; CSF: cerebrospinal fluid; Cts: Controls; CXCL1: C-X-C motif chemokine ligand 1; d: day; ELISA: enzyme-linked immunosorbent assay; EPDS: Edinburgh Postnatal Depression Scale; FGF-23: Fibroblast growth factor 23; G-CSF: Granulocyte colony-stimulating factor; GM-CSF: Granulocyte-macrophage colony-stimulating factor; gw: gestational weeks; h: hours; HAM-D or HDRS: Hamilton Depression Rating Scale; HGF: Hepatocyte growth factor; HPLC: High performance liquid chromatography; hs: high-sensitivity; IBS: Irritable bowel syndrome; IFN- γ : Interferon gamma; IL-: Interleukin-; IL-1 β : Interleukin 1 beta; IL-1RA: Interleukin 1 receptor antagonist; IL6R: Interleukin 6 Receptor; KA: Kynurenic acid; K/T: kynurenine/tryptophan (K/T); KYN: Kynurenine; LIF-R: Leukemia inhibitory factor-receptor; LOD: Limit of detection; LPS: Lipopolysaccharides; M: Mean; MADRS: Montgomery Asberg Depression Rating Scale; MCP-1: Monocyte chemotactic protein 1; MCP-2: Monocyte chemotactic protein; MIF: Macrophage migration inhibitory factor; MINI: The Mini International Neuropsychiatric Interview; MIP-1 α : Macrophage inflammatory protein-1 alpha; MIP-1 β : Macrophage inflammatory protein-1 beta; mo: months; ND: non-depressive group; NPX: normalized protein expression; NR: not reported; NS: not significant results; PD: postpartum depressive group; PP: postpartum; PPD: Postpartum depression; PSS: Perceived Stress Scale; SCID: Structured Clinical Interview for DSM; SDF-1 α : The stromal cell-derived factor 1 alpha; sgp130: soluble glycoprotein 130; SIGH-ADS29: The Structured Interview Guide for the Hamilton Depression Rating Scale—Atypical Depression Symptoms (SIGH-ADS29); SIGH-SAD: Structured Interview Guide for the Hamilton Depression Rating Scale - Seasonal Affective Disorders; SIRT2: Sirtuin-2; STAI: The State-Trait Anxiety Inventory; STAMPB: STAM Binding Protein; ST1A1: Sulfotransferase Family 1A Member 1u; T: Total; TG: Temporary gestational depressive group; TNF- α : Tumor necrosis factor alfa; TRANCE: Tumor necrosis factor ligand superfamily member 11; TRP: Tryptophan; vs: versus; wks: weeks; ZDS: Zung Depression Rating Scale; \uparrow : Increase; \downarrow : Decrease; (+): positive; (-): negative.

References

1. Simpson W, Steiner M, Coote M, Frey BN. Relationship between inflammatory biomarkers and depressive symptoms during late pregnancy and the early postpartum period: a longitudinal study. *Brazilian Journal of Psychiatry*. 2016;38:190-6.
2. Boufidou F, Lambrinouadaki I, Argeitis J, Zervas IM, Pliatsika P, Leonardou AA, et al. CSF and plasma cytokines at delivery and postpartum mood disturbances. *Journal of affective disorders*. 2009;115(1-2):287-92.
3. Sha Q, Madaj Z, Keaton S, Escobar Galvis ML, Smart L, Krzyzanowski S, et al. Cytokines and tryptophan metabolites can predict depressive symptoms in pregnancy. *Translational psychiatry*. 2022;12(1):1-8.
4. Nazzari S, Molteni M, Valtorta F, Comai S, Frigerio A. Prenatal IL-6 levels and activation of the tryptophan to kynurenine pathway are associated with depressive but not anxiety symptoms across the perinatal and the post-partum period in a low-risk sample. *Brain, Behavior, and Immunity*. 2020;89:175-83.
5. Dantzer R, O'connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nature reviews neuroscience*. 2008;9(1):46-56.
6. Dantzer R. Neuroimmune interactions: from the brain to the immune system and vice versa. *Physiological reviews*. 2018;98(1):477-504.
7. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. *Trends in immunology*. 2006;27(1):24-31.
8. Lasselin J, Elsenbruch S, Lekander M, Axelsson J, Karshikoff B, Grigoleit JS, et al. Mood disturbance during experimental endotoxemia: Predictors of state anxiety as a psychological component of sickness behavior. *Brain Behav Immun*. 2016;57:30-7.
9. Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: depression fans the flames and feasts on the heat. *American Journal of Psychiatry*. 2015;172(11):1075-91.
10. Mor G, Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune system at the implantation site. *Annals of the new York Academy of Sciences*. 2011;1221(1):80-7.
11. Brown MB, von Chamier M, Allam AB, Reyes L. M1/M2 macrophage polarity in normal and complicated pregnancy. *Frontiers in immunology*. 2014;5:606.
12. Ernerudh J, Berg G, Mjösberg J. Regulatory T helper cells in pregnancy and their roles in systemic versus local immune tolerance. *American journal of reproductive immunology*. 2011;66:31-43.
13. Zhang Y-H, He M, Wang Y, Liao A-H. Modulators of the balance between M1 and M2 macrophages during pregnancy. *Frontiers in immunology*. 2017;8:120.
14. Sawyer KM. The role of inflammation in the pathogenesis of perinatal depression and offspring outcomes. *Brain, Behavior, & Immunity-Health*. 2021;18:100390.
15. Westfall S, Caracci F, Zhao D, Wu Q-I, Frolinger T, Simon J, et al. Microbiota metabolites modulate the T helper 17 to regulatory T cell (Th17/Treg) imbalance promoting resilience to stress-induced anxiety-and depressive-like behaviors. *Brain, behavior, and immunity*. 2021;91:350-68.
16. Piccinni M-P, Lombardelli L, Logiodice F, Kullolli O, Parronchi P, Romagnani S. How pregnancy can affect autoimmune diseases progression? *Clinical and Molecular Allergy*. 2016;14(1):1-9.
17. Norman JE, Bollapragada S, Yuan M, Nelson SM. Inflammatory pathways in the mechanism of parturition. *BMC pregnancy and childbirth*. 2007;7(1):1-4.
18. Menon R, Bonney EA, Condon J, Mesiano S, Taylor RN. Novel concepts on pregnancy clocks and alarms: redundancy and synergy in human parturition. *Human reproduction update*. 2016;22(5):535-60.

19. Okagbue HI, Adamu PI, Bishop SA, Oguntunde PE, Opanuga AA, Akhmetshin EM. Systematic review of prevalence of antepartum depression during the trimesters of pregnancy. *Open access Macedonian journal of medical sciences*. 2019;7(9):1555.
20. Romano M, Cacciatore A, Giordano R, La Rosa B. Postpartum period: three distinct but continuous phases. *Journal of prenatal medicine*. 2010;4(2):22.
21. Bränn E, Edvinsson Å, Rostedt Punga A, Sundström-Poromaa I, Skalkidou A. Inflammatory and anti-inflammatory markers in plasma: from late pregnancy to early postpartum. *Scientific reports*. 2019;9(1):1-10.
22. Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. *Biological psychiatry*. 2016;80(1):40-52.
23. La Rocca C, Carbone F, Longobardi S, Matarese G. The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus. *Immunology letters*. 2014;162(1):41-8.
24. Buglione-Corbett R, Deligiannidis KM, Leung K, Zhang N, Lee M, Rosal MC, et al. Expression of inflammatory markers in women with perinatal depressive symptoms. *Archives of women's mental health*. 2018;21(6):671-9.
25. Bränn E, Papadopoulos F, Fransson E, White R, Edvinsson Å, Hellgren C, et al. Inflammatory markers in late pregnancy in association with postpartum depression—a nested case-control study. *Psychoneuroendocrinology*. 2017;79:146-59.
26. Lambert M, Gressier F. Inflammatory biomarkers and postpartum depression: a systematic review of literature. *Canadian Journal of psychiatry Revue Canadienne de Psychiatrie*. 2019;64(7):471-81.
27. Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. *Brain, behavior, and immunity*. 2020;87:901-9.
28. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
29. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Systematic reviews*. 2021;10(1):1-11.
30. Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2011;2(1):1-12.
31. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000.
32. Herzog R, Álvarez-Pasquin M, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. *BMC public health*. 2013;13(1):1-17.
33. Shelton MM, Schminkey DL, Groer MW. Relationships among prenatal depression, plasma cortisol, and inflammatory cytokines. *Biological research for nursing*. 2015;17(3):295-302.
34. Venkatesh KK, Meeker JD, Cantonwine DE, McElrath TF, Ferguson KK. Association of antenatal depression with oxidative stress and impact on spontaneous preterm birth. *J Perinatol*. 2019;39(4):554-62.
35. Haeri S, Baker AM, Ruano R. Do pregnant women with depression have a pro-inflammatory profile? *Journal of Obstetrics and Gynaecology Research*. 2013;39(5):948-52.
36. Edvinsson Å, Bränn E, Hellgren C, Freyhult E, White R, Kamali-Moghaddam M, et al. Lower inflammatory markers in women with antenatal depression brings the M1/M2 balance into focus from a new direction. *Psychoneuroendocrinology*. 2017;80:15-25.

37. Miller ES, Sakowicz A, Roy A, Yang A, Sullivan JT, Grobman WA, et al. Plasma and cerebrospinal fluid inflammatory cytokines in perinatal depression. *American journal of obstetrics and gynecology*. 2019;220(3):271. e1-. e10.
38. Chang JP-C, Lin C-Y, Lin P-Y, Shih Y-H, Chiu T-H, Ho M, et al. Polyunsaturated fatty acids and inflammatory markers in major depressive episodes during pregnancy. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2018;80:273-8.
39. Bianciardi E, Barone Y, Serro VL, De Stefano A, Giacchetti N, Aceti F, et al. Inflammatory markers of perinatal depression in women with and without history of trauma. *Rivista di Psichiatria*. 2021;56(5):237-45.
40. Serati M, Esposito CM, Grassi S, Bollati V, Barkin JL, Buoli M. The Association between Plasma ERVWE1 Concentrations and Affective Symptoms during Pregnancy: Is This a Friendly Alien? *International Journal of Environmental Research and Public Health*. 2020;17(24):9217.
41. Keane JM, Khashan AS, McCarthy FP, Kenny LC, Collins JM, O'Donovan S, et al. Identifying a biological signature of prenatal maternal stress. *JCI insight*. 2021;6(2).
42. Cassidy-Bushrow AE, Peters RM, Johnson DA, Templin TN. Association of depressive symptoms with inflammatory biomarkers among pregnant African-American women. *Journal of reproductive immunology*. 2012;94(2):202-9.
43. Karlsson L, Nousiainen N, Scheinin NM, Maksimow M, Salmi M, Lehto SM, et al. Cytokine profile and maternal depression and anxiety symptoms in mid-pregnancy—the FinnBrain Birth Cohort Study. *Archives of women's mental health*. 2017;20(1):39-48.
44. Ruiz RJ, Stowe RP, Goluszko E, Clark MC, Tan A. The relationships among acculturation, body mass index, depression, and interleukin 1-receptor antagonist in Hispanic pregnant women. *Ethnicity and Disease*. 2007;17(2):338.
45. Christian LM, Franco A, Glaser R, Iams JD. Depressive symptoms are associated with elevated serum proinflammatory cytokines among pregnant women. *Brain, behavior, and immunity*. 2009;23(6):750-4.
46. Roomruangwong C, Kanchanatawan B, Sirivichayakul S, Anderson G, Carvalho AF, Duleu S, et al. IgA/IgM responses to tryptophan and tryptophan catabolites (TRYCATs) are differently associated with prenatal depression, physio-somatic symptoms at the end of term and premenstrual syndrome. *Molecular neurobiology*. 2017;54(4):3038-49.
47. Teshigawara T, Mouri A, Kubo H, Nakamura Y, Shiino T, Okada T, et al. Changes in tryptophan metabolism during pregnancy and postpartum periods: Potential involvement in postpartum depressive symptoms. *Journal of Affective Disorders*. 2019;255:168-76.
48. Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpé S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. *Life sciences*. 2002;71(16):1837-48.
49. Maes M, Ombelet W, Verkerk R, Bosmans E, Scharpe S. Effects of pregnancy and delivery on the availability of plasma tryptophan to the brain: relationships to delivery-induced immune activation and early post-partum anxiety and depression. *Psychological medicine*. 2001;31(5):847-58.
50. Scrandis DA, Siddiqi HA, Postolache TT. No impact of gonadal steroid levels on the association between C-reactive protein and prepartum depression scores. 2010.
51. Scrandis DA, Langenberg P, Tonelli LH, Sheikh TM, Manogura AC, Alberico LA, et al. Prepartum depressive symptoms correlate positively with C-reactive protein levels and negatively with tryptophan levels: a preliminary report. *International journal of child health and human development: IJCHD*. 2008;1(2):167.
52. Achtyes E, Keaton SA, Smart L, Burmeister AR, Heilman PL, Krzyzanowski S, et al. Inflammation and kynurenine pathway dysregulation in post-partum women with severe and suicidal depression. *Brain, behavior, and immunity*. 2020;83:239-47.

53. Zhou Z, Guille C, Ogunrinde E, Liu R, Luo Z, Powell A, et al. Increased systemic microbial translocation is associated with depression during early pregnancy. *Journal of psychiatric research*. 2018;97:54-7.
54. Krause D, Jobst A, Kirchberg F, Kieper S, Härtl K, Kästner R, et al. Prenatal immunologic predictors of postpartum depressive symptoms: a prospective study for potential diagnostic markers. *European archives of psychiatry and clinical neuroscience*. 2014;264(7):615-24.
55. Okun ML, Luther J, Prather AA, Perel JM, Wisniewski S, Wisner KL. Changes in sleep quality, but not hormones predict time to postpartum depression recurrence. *Journal of affective disorders*. 2011;130(3):378-84.
56. Groer M, Davis M, Casey K, Short B, Smith K, Groer S. Neuroendocrine and immune relationships in postpartum fatigue. *MCN: The American Journal of Maternal/Child Nursing*. 2005;30(2):133-8.
57. Christian LM, Kowalsky JM, Mitchell AM, Porter K. Associations of postpartum sleep, stress, and depressive symptoms with LPS-stimulated cytokine production among African American and White women. *Journal of Neuroimmunology*. 2018;316:98-106.
58. Dong T, Zhao X, Yang Z, editors. Concept and approach of human signal-molecular-profiling database: a pilot study on depression using Lab-on-chips. 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC); 2013: IEEE.
59. Fransson E, Dubicke A, Byström B, Ekman-Ordeberg G, Hjelmstedt A, Lekander M. Negative emotions and cytokines in maternal and cord serum at preterm birth. *American Journal of Reproductive Immunology*. 2012;67(6):506-14.
60. Gruenberg DA, Wright RJ, Visness CM, Jaffee KF, Bloomberg GR, Cruikshank WW, et al. Relation between stress and cytokine responses in inner-city mothers. *Annals of Allergy, Asthma & Immunology*. 2015;115(5):439-45. e3.
61. Kondo N, Suda Y, Nakao A, Oh-Oka K, Suzuki K, Ishimaru K, et al. Maternal psychosocial factors determining the concentrations of transforming growth factor-beta in breast milk. *Pediatric Allergy and Immunology*. 2011;22(8):853-61.
62. Kianbakht S, Mashhadi E, Jamillian HR, Ghazavi A. Immune phenomena in neonates of women with depression during pregnancy: a case-control study. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2013;26(6):608-10.
63. Groer MW, Davis MW. Cytokines, infections, stress, and dysphoric moods in breastfeeders and formula feeders. *Journal of Obstetric, Gynecologic & Neonatal Nursing*. 2006;35(5):599-607.
64. Groer MW, Morgan K. Immune, health and endocrine characteristics of depressed postpartum mothers. *Psychoneuroendocrinology*. 2007;32(2):133-9.
65. Maes M, Ombet W, Libbrecht I, Stevens K, Kenis G, De Jongh R, et al. Effects of pregnancy and delivery on serum concentrations of Clara Cell Protein (CC16), an endogenous anticytokine: lower serum CC16 is related to postpartum depression. *Psychiatry research*. 1999;87(2-3):117-27.
66. Liu H, Zhang Y, Gao Y, Zhang Z. Elevated levels of Hs-CRP and IL-6 after delivery are associated with depression during the 6 months post partum. *Psychiatry research*. 2016;243:43-8.
67. Bränn E, Fransson E, White RA, Papadopoulos FC, Edvinsson Å, Kamali-Moghaddam M, et al. Inflammatory markers in women with postpartum depressive symptoms. *Journal of neuroscience research*. 2020;98(7):1309-21.
68. Corwin EJ, Johnston N, Pugh L. Symptoms of postpartum depression associated with elevated levels of interleukin-1 beta during the first month postpartum. *Biological research for nursing*. 2008;10(2):128-33.
69. Roomruangwong C, Kanchanatawan B, Sirivichayakul S, Mahieu B, Nowak G, Maes M. Lower serum zinc and higher CRP strongly predict prenatal depression and physio-somatic

- symptoms, which all together predict postnatal depressive symptoms. *Molecular neurobiology*. 2017;54(2):1500-12.
70. Corwin EJ, Pajer K, Paul S, Lowe N, Weber M, McCarthy DO. Bidirectional psychoneuroimmune interactions in the early postpartum period influence risk of postpartum depression. *Brain, behavior, and immunity*. 2015;49:86-93.
71. Paul S, Corwin EJ. Identifying clusters from multidimensional symptom trajectories in postpartum women. *Research in Nursing & Health*. 2019;42(2):119-27.
72. Osborne LM, Yenokyan G, Fei K, Kraus T, Moran T, Monk C, et al. Innate immune activation and depressive and anxious symptoms across the peripartum: an exploratory study. *Psychoneuroendocrinology*. 2019;99:80-6.
73. Cheng C, Pickler R. Perinatal stress, fatigue, depressive symptoms, and immune modulation in late pregnancy and one month postpartum. *The Scientific World Journal*. 2014;2014.
74. Azar R, Mercer D. Mild depressive symptoms are associated with elevated C-reactive protein and proinflammatory cytokine levels during early to midgestation: a prospective pilot study. *Journal of women's health*. 2013;22(4):385-9.
75. Maes M, Lin AH, Ombélet W, Stevens K, Kenis G, De Jongh R, et al. Immune activation in the early puerperium is related to postpartum anxiety and depressive symptoms. *Psychoneuroendocrinology*. 2000;25(2):121-37.
76. Nazzari S, Fearon P, Rice F, Ciceri F, Molteni M, Frigerio A. The biological underpinnings of perinatal depressive symptoms: A multi-systems approach. *Journal of Affective Disorders*. 2020;274:1004-12.
77. Cervellati C, Trentini A, Pecorelli A, Valacchi G. Inflammation in neurological disorders: the thin boundary between brain and periphery. *Antioxidants & Redox Signaling*. 2020;33(3):191-210.
78. Miller AH. Beyond depression: the expanding role of inflammation in psychiatric disorders. *World Psychiatry*. 2020;19(1):108.
79. Brann E, Skalkidou A, Schwarz J, Papadopoulos FC, Sundstrom Poromaa I, Fransson E. Longitudinal assessment of inflammatory markers in the peripartum period by depressive symptom trajectory groups. *Brain Behav Immun Health*. 2022;22:100468.
80. Kling MA, Alesci S, Csako G, Costello R, Luckenbaugh DA, Bonne O, et al. Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. *Biol Psychiatry*. 2007;62(4):309-13.
81. Panagiotakos DB, Pitsavos C, Chrysohoou C, Tsetsekou E, Papageorgiou C, Christodoulou G, et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. *Eur Heart J*. 2004;25(6):492-9.
82. Scrandis DA, Langenberg P, Tonelli LH, Sheikh TM, Manogura AC, Alberico LA, et al. Prepartum Depressive Symptoms Correlate Positively with C-Reactive Protein Levels and Negatively with Tryptophan Levels: A Preliminary Report. *Int J Child Health Hum Dev*. 2008;1(2):167-74.
83. Pasco JA, Nicholson GC, Williams LJ, Jacka FN, Henry MJ, Kotowicz MA, et al. Association of high-sensitivity C-reactive protein with de novo major depression. *Br J Psychiatry*. 2010;197(5):372-7.
84. O'Mahony SM, Clarke G, Borre Y, Dinan TG, Cryan J. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. *Behavioural brain research*. 2015;277:32-48.
85. Badawy AA. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. *International Journal of Tryptophan Research*. 2017;10:1178646917691938.
86. Zhu CB, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. *Neuropsychopharmacology*. 2010;35(13):2510-20.


87. Sperner-Unterweger B, Kohl C, Fuchs D. Immune changes and neurotransmitters: possible interactions in depression? *Prog Neuropsychopharmacol Biol Psychiatry*. 2014;48:268-76.
88. Worthen RJ, Beurel E. Inflammatory and neurodegenerative pathophysiology implicated in postpartum depression. *Neurobiol Dis*. 2022;165:105646.
89. Yu Y, Liang HF, Chen J, Li ZB, Han YS, Chen JX, et al. Postpartum Depression: Current Status and Possible Identification Using Biomarkers. *Front Psychiatry*. 2021;12:620371.
90. Mac Giollabhui N. Inflammation and depression: research designs to better understand the mechanistic relationships between depression, inflammation, cognitive dysfunction, and their shared risk factors. *Brain, Behavior, & Immunity-Health*. 2021;15:100278.
91. Jallo N, Brown L, Elswick R, Kinser P, Salisbury AL. Happiness in Pregnant African American Women: What Are the Biobehavioral Correlates? *The Journal of Perinatal & Neonatal Nursing*. 2021;35(1):19-28.
92. Blackmore ER, Moynihan JA, Rubinow DR, Pressman EK, Gilchrist M, O'Connor TG. Psychiatric symptoms and proinflammatory cytokines in pregnancy. *Psychosomatic medicine*. 2011;73(8):656.
93. Lahti-Pulkkinen M, Girchenko P, Robinson R, Lehto SM, Toffol E, Heinonen K, et al. Maternal depression and inflammation during pregnancy. *Psychological medicine*. 2020;50(11):1839-51.
94. Blackmore ER, Groth SW, Chen D-G, Gilchrist MA, O'Connor TG, Moynihan JA. Depressive symptoms and proinflammatory cytokines across the perinatal period in African American women. *Journal of Psychosomatic Obstetrics & Gynecology*. 2014;35(1):8-15.
95. Maes M, Lin A-h, Ombelet W, Stevens K, Kenis G, De Jongh R, et al. Immune activation in the early puerperium is related to postpartum anxiety and depressive symptoms. *Psychoneuroendocrinology*. 2000;25(2):121-37.
96. Skalkidou A, Sylvén SM, Papadopoulos FC, Olovsson M, Larsson A, Sundström-Poromaa I. Risk of postpartum depression in association with serum leptin and interleukin-6 levels at delivery: A nested case-control study within the UPPSAT cohort. *Psychoneuroendocrinology*. 2009;34(9):1329-37.
97. Miller ES, Hoxha D, Pinheiro E, Grobman WA, Wisner KL. The association of serum C-reactive protein with the occurrence and course of postpartum depression. *Archives of women's mental health*. 2019;22(1):129-32.

Supporting information

S1 Table. Search terms.

S2 Table. Studies reporting results between depression and inflammation as secondary data.

Identification of studies via databases and registers



*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).

**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>